RBL Communications
  • Home
  • About
  • Services
  • Investment Hub
  • Contact
Select Page

Michael Frank, CEO of Revive Therapeutics provides update on the Company

by RBL | Apr 20, 2020

 

https://rblcommunications.com/wp-content/uploads/2020/04/Revive-Interview-a.mp4

CSE :  RVV

Sign Up To Our Mailing List

Recent Posts

  • Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
    May 12, 2025 2:38 pm
  • Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
    April 10, 2025 10:24 am
  • Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
    April 1, 2025 9:13 am
  • Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
    February 3, 2025 10:02 am
  • Home
  • About
  • Services
  • Investment Hub
  • Contact
  • Facebook
  • X
© COPYRIGHT 2025. RBL Communications Inc. ALL RIGHTS RESERVED.